US-based biotechnology company Imunon has reported positive results from its Phase II OVATION 2 trial of IMNN-001 for ovarian ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Momentum Continues with Presentations at ASCO and ESMO Imunon, Inc.

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response  Results, presented simultaneously in oral ...

IMUNON reports promising Phase 2 results for IMNN-001 in ovarian cancer, presenting at ASCO 2025 and publishing in Gynecologic Oncology. IMUNON, Inc. has announced significant progress in cancer ...

Imunon (IMNN) stock rocketed higher on Friday after the pharmaceutical company announced positive results from its Phase 2 OVATION 2 Study of IMNN-001. This study was focused on using IMNN-001 as a ...

As I mark my first year as President and CEO of IMUNON, I am thrilled to share the progress we have made in advancing our mission to transform cancer treatment. With robust fundamentals and ...

IMUNON, Inc. announced promising results from its Phase 2 OVATION 2 Study of IMNN-001, an investigational therapy for advanced ovarian cancer, which demonstrated significant improvements in ...

“As we continue to evaluate findings from our Phase 2 OVATION 2 Study, the data show consistently strong improvement in overall and progression-free survival, suggesting that IMNN-001 may drive ...

In the run up to the 2025 annual ASCO meeting, IMUNON (Nasdaq: IMNN) is moving into a Phase III trial with its lead candidate ...